Floatz logo

Thiotepa

Bone Marrow Failure Syndrome

Fred Hutchinson Cancer CenterSmall moleculePhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Bone Marrow Failure Syndrome cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2/3BBB
Cyclophosphamide
Memorial Sloan Kettering Cancer Center
Phase 2/3BBB
Alemtuzumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2/3BB
Busulfanum
Memorial Sloan Kettering Cancer Center
Phase 2/3BB
Methotrexate
Fred Hutchinson Cancer Center
Phase 2BB

View all 30 →

Same molecule, other indications

Thiotepa is also rated in:

graft versus host diseaseActive
BBB
Indicative · Phase 4
73 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmActive
BBB
Indicative · Phase 2/3
72 / 100
View asset →
juvenile myelomonocytic leukemiaActive
BBB
Indicative · Phase 3
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →